Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays. Bruce Feinberg, DO: I asked Kenna. You can't talk for her. Kenna R.

Jessica Donington, MD, MSCR: There’s one more factor that in 2021 plays a huge role in how we determine upfront treatment and treatment plans altogether and that’s something called molecular testing.

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

ROCKVILLE, Md. – March 31, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, and pathologist Michael Laposata , M.D. , Ph.D., today ...

ROCKVILLE, Md. – August 19, 2024 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, and world-renowned pathologist Michael Laposata, MD, PhD ...

IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...

Antimicrobial resistance (AMR) remains a major global healthcare challenge, undermining the effectiveness of treatments for common infections and threatening modern medical advances. Improved ...

Please provide your email address to receive an email when new articles are posted on . During the past 2 decades, Endocrine Today has reported on the latest developments in treating thyroid cancer.

Caris Life Sciences announced this week that it will be broadening its partnership with Epic, integrating its molecular testing portfolio with Epic's Orders and Results Anywhere network. Caris offers ...

3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...